Key Drivers
- Cash Generation
- High Leverage
- Thin Coverage
AIAI Summary
GRFS is shifting from a balance-sheet stress case to a modest operational recovery story—refinancing eases near-term maturities and Biopharma/immunoglobulin growth plus positive free cash flow support the thesis—but leverage and interest burden remain the key constraint until the stock can reclaim 7.25–7.31 resistance and prove the turnaround is durable.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Generation
- •High Leverage
- •Thin Coverage
GRFS is profitable and cash-generative with covered dividends and a modest valuation, but high leverage and thin interest coverage make the investment case dependent on steady operating performance.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •$7.00 support
- •Breakout needed
GRFS remains in a weak downtrend over the last month, but holding near $7.00 and rebounding on July 2 suggests near-term support, with $7.25–$7.31 as the first breakout test.
Rebounded on
Sentiment & News
Key News Insights:
- •Biopharma Strength
- •Debt Refinance
- •FESILTY Launch
Grifols is gaining momentum with strong Q1 biopharma growth, lower refinancing risk after early debt extension, and the U.S. launch of FESILTY adding a new commercial product.
This is a positive catalyst for GRFS, supporting improved margins, reduced balance-sheet risk, and a clearer path to commercial growth
Similar Companies in Healthcare
Other companies in the same sector with AI ratings